Drug Applications Face Rejection As China FDA Starts 'Intensive Review'
This article was originally published in SRA
In a rare move, the China Food and Drug Administration has rejected 11 new drug applications (NDAs) from eight companies that were in its review queue, signaling more action to come as the agency increases punishments for clinical data forgery and prepares another intensive review campaign, its third in a decade.
You may also be interested in...
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.
China releases technical requirements for foreign drug makers to register their chemical drugs in the country, and issues patent linkage details, which a legal expert says needs to be closely examined.